SCYNEXIS Inc. (SCYX) and Akorn Inc. (NASDAQ:AKRX) Comparison side by side

This is a contrast between SCYNEXIS Inc. (NASDAQ:SCYX) and Akorn Inc. (NASDAQ:AKRX) based on their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation. The two companies are Drugs – Generic and they also compete with each other.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SCYNEXIS Inc. N/A 279.99 12.47M -0.58 0.00
Akorn Inc. 694.02M 0.61 401.91M -2.23 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 represents SCYNEXIS Inc. (NASDAQ:SCYX) and Akorn Inc. (NASDAQ:AKRX)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
SCYNEXIS Inc. 0.00% -78.1% -39.8%
Akorn Inc. -57.91% -33.4% -13.9%

Volatility and Risk

SCYNEXIS Inc.’s volatility measures that it’s 133.00% more volatile than S&P 500 due to its 2.33 beta. Akorn Inc. on the other hand, has 2.75 beta which makes it 175.00% more volatile compared to S&P 500.

Liquidity

SCYNEXIS Inc. has a Current Ratio of 4.5 and a Quick Ratio of 4.5. Competitively, Akorn Inc.’s Current Ratio is 3.5 and has 2.5 Quick Ratio. SCYNEXIS Inc.’s better ability to pay short and long-term obligations than Akorn Inc.

Analyst Recommendations

The next table highlights the delivered recommendations and ratings for SCYNEXIS Inc. and Akorn Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
SCYNEXIS Inc. 0 0 2 3.00
Akorn Inc. 0 1 2 2.67

$4.5 is SCYNEXIS Inc.’s average target price while its potential upside is 200.00%. Akorn Inc. on the other hand boasts of a $7 average target price and a 107.10% potential upside. Based on the analysts view we can conclude, SCYNEXIS Inc. is looking more favorable than Akorn Inc.

Insider & Institutional Ownership

Institutional investors owned 36.6% of SCYNEXIS Inc. shares and 76.8% of Akorn Inc. shares. About 2.1% of SCYNEXIS Inc.’s share are owned by insiders. Comparatively, Akorn Inc. has 1.9% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
SCYNEXIS Inc. -1.56% 23.53% 61.95% -6.67% -24.1% 161.57%
Akorn Inc. -1% 5.85% -43.14% -72.85% -77.69% 17.4%

For the past year SCYNEXIS Inc. was more bullish than Akorn Inc.

Summary

SCYNEXIS Inc. beats Akorn Inc. on 8 of the 11 factors.

SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.

Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets specialized generic and branded pharmaceuticals, over-the-counter (OTC) drug products, and animal health products in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. This segmentÂ’s primary products include Atropine Sulfate Ophthalmic Solution; Clobetasol Propionate Cream And Ointment; Ephedrine Sulfate Injection; Lidocaine Ointment; Methylene Blue Injection; Myorisan soft gelatin capsules; Nembutal sodium solution; Phenylephrine Hydrochloride Ophthalmic Solution; and Zioptan tafluprost ophthalmic solution. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.